Systematic review and meta-analysis of somatostatin analogues for the treatment of pancreatic fistula
| Autor: | E. A. J. Rauws, D. J. Gouma, H. L. van Westreenen, S. L. Gans, Jordy J. S. Kiewiet, Marja A. Boermeester |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
medicine.medical_specialty Octreotide Gastroenterology Peptides Cyclic law.invention Pancreatic Fistula Postoperative Complications Randomized controlled trial law Internal medicine medicine Humans Aged Randomized Controlled Trials as Topic Surrogate endpoint business.industry Odds ratio Middle Aged medicine.disease Confidence interval Surgery medicine.anatomical_structure Somatostatin Treatment Outcome Pancreatic fistula Meta-analysis Pancreas business |
| Zdroj: | The British journal of surgery. 99(6) |
| ISSN: | 1365-2168 |
| Popis: | Background Somatostatin analogues are used for the treatment of pancreatic fistula, with the aim of achieving fistula closure or reduction of output. Method MEDLINE, Embase and Cochrane databases were searched systematically for relevant articles followed by hand-searching of reference lists. Data on patient recruitment, intervention and outcome were extracted and meta-analysis performed where reasonable. Results Seven randomized clinical trials met the inclusion criteria and included a total of 297 patients with fistulas of the gastrointestinal tract; of these, 102 patients had fistulas of pancreatic origin. Pooling of closure rates showed no significant difference between patients treated with somatostatin analogues compared with controls: odds ratio 1·52 (95 per cent confidence interval 0·88 to 2·61). Owing to inconsistent descriptions, pooling of results was not possible for other endpoints, such as time to fistula closure. Conclusion There is no solid evidence that somatostatin analogues result in a higher closure rate of pancreatic fistula compared with other treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text